Clinical trial SADAL
SADAL - A Phase 2b Open-label study of Selinexor (KPT-330) in Patients with Relapsed/
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Karyopharm |
| EudraCT Identifier | 2014-001977-15 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02227251 |
| Inclusion criteria | At least 2 but no more than 5 previous systemic regimens - For patients whose most recent systemic anti-DLBCL therapy induced a PR or CR, at least 60 days must have elapsed since the end of that therapy |
| Last update |